NeuroRestore - a novel therapy for Alzheimer´s disease
|Coordinator||AlzeCure Pharma AB|
|Funding from Vinnova||SEK 500 000|
|Project duration||October 2017 - May 2018|
Purpose and goal
Alzheimer´s disease (AD) is the most common form of dementia and one of the most devastating the diseases we face today from a socio-economic perspective. AlzeCure Pharma is a Swedish pharmaceutical company whose goal is to develop NeuroRestore, one innovative symptomatic drug therapy with disease modifying potential for the treatment of AD. We have used the funding to do a comprehensive feasibility study where we have developed a business plan to guide the project towards clinical validation and subsequent commercialization of the therapy.
Expected results and effects
The feasibility study has demonstrated strong clinical and commercial potential of NeuroRestore. We have found that the increasing prevalence of AD and other cognitive disorders, coupled with the need for novel symptomatic therapies with innovative mechanisms of action to the AD market, create a unique business opportunity for AlzeCure. NeuroRestore has the potential to become a real game changer in the area of cognitive disorders.
Planned approach and implementation
During the reporting period, we have conducted a feasibility study where we worked in parallel with both databases and external parties to develop a comprehensive analysis of the indication area, commercial opportunities and clinical plan.